On the afternoon of March 27, Ivor Ralph Edwards, the former director of the world health organization's Uppsala monitoring center, and experts including Helena Skoeld and Zhurong Liu, accompanied by the leaders of Shenzhen Market and Quality Supervision and Management Committee and Peng Shan bureau, went to Shenzhen Microchip Pharmaceutical co., ltd., a subsidiary of Shenzhen CHIPSCREEN BIOSCIENCES co., ltd., to carry out research.

Dr. Lu Xianping, the president of CHIPSCREEN BIOSCIENCES, reported to the visiting experts and leaders of the Market and Quality Supervision and Management Committee on the work of monitoring the adverse reactions of the first original anti-tumor drug Chidamide (Epidaza?) in our country after being launched on the market. In order to better understand the characteristics of adverse reactions in the real world after Chidamide's listing, CHIPSCREEN BIOSCIENCES has established a set of active post-marketing drug safety monitoring system to carry out post-marketing key monitoring of Chidamide. In the past two years since the implementation of the project, more than 2,000 patients' usage data have been collected and analyzed and reported in accordance with relevant national laws and regulations.

Uppsala experts gave high recognition and praise to the post-marketing active monitoring system established by CHIPSCREEN BIOSCIENCES and the key monitoring work carried out, saying that Uppsala monitoring center will vigorously carry out cooperation with Shenzhen biopharmaceutical enterprises to make contribution to improve the level of " Shenzhen Quality".